Australian Genomics Of Chronic Allograft Dysfunction Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorWestern Sydney Local Health District
About this trial
The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.
Eligibility criteria
Qualifiers
Living or deceased donor kidney transplant candidate.
Biological sex: any
Ages: 18-75 years.
Subject must be able to understand and provide informed consent.
Disqualifiers
Presensitization in living donor recipients prior to transplantation, as determined by site-specific standards, OR positive cross match according to site specific technique in cadaveric donor recipients.
Recipients of multiple organ transplants, with the exception of kidney/pancreas transplants.
Inability or unwillingness of a participant to give written informed consent or comply with study protocol
High risk populations including pregnant women, children less than 18 years and prisoners will not be included in the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov